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Brief CommuniCations
Approximately 50% of US adults are nonadherent to their 
antihypertensive drug regimens, contributing to uncon-
trolled hypertension, increased health care costs, and worse 
cardiovascular prognosis.1–3 The latest US hypertension 
guidelines do not discuss whether there is a role for incor-
porating interclass differences in adherence for prescribing 
decisions.4 Pharmacy refill and claims data suggest that there 
are differences in adherence among the most commonly pre-
scribed antihypertensive medication classes.5,6 Compared to 
angiotensin receptor blocking agents (ARB), angiotensin-
converting enzyme inhibitors (ACEI), and calcium channel 
blockers (CCB), thiazide diuretics, and beta-blockers have 
increased gaps between prescription refills and are more 
likely to be discontinued, possibly due to increased adverse 
effects of medications from these classes.5–7 According to a 
recent meta-analysis, mean persistence to antihypertensive 
medications was 65% for ARBs vs. only 28% and 51% for 
beta-blockers and diuretics, respectively.6
These prior studies have focused on patients initiating a 
single blood pressure (BP) medication and have only exam-
ined differences in refill patterns. However, in practice, 
physicians must often make prescribing decisions among 
patients who require multiple agents to control their BP, 
and refilling prescriptions is but one component of adher-
ence behavior.8–10 Patients must also take their medications 
on a day-to-day basis to obtain the maximal benefit from 
their antihypertensive medications.11 To our knowledge, 
no prior study has analyzed whether antihypertensive drug 
class is associated with differences in day-to-day adherence 
behavior, particularly in patients on multiple chronic BP 
medications.
The aim of this study was to determine whether inter-
class differences exist in electronically measured, day-to-day 
adherence to antihypertensive medications among patients 
with persistently uncontrolled hypertension. Consistent with 
the pharmacy refill data, we hypothesized that adherence 
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BACKGROUND
Medication adherence is essential to optimizing blood pressure (BP) con-
trol. Prior research has demonstrated differences in pharmacy refill pat-
terns according to antihypertensive drug class. No prior study has assessed 
the association between drug class and day-to-day adherence.
METHODS
Between 2011 and 2014, we enrolled a convenience sample of 149 
patients with persistently uncontrolled hypertension from two inner-
city clinics and concurrently measured adherence of up to four antihy-
pertensive medications using electronic pillboxes during the interval 
between two primary care visits. The main outcome was mean per-
cent of days adherent to each drug. Mixed effects regression analyses 
were used to assess the association between drug class and adherence 
adjusting for age, gender, race, ethnicity, education, health insurance, 
coronary artery disease, heart failure, chronic kidney disease, diabetes, 
number of medications, days monitored, and dosing frequency.
RESULTS
The mean age was 64  years; 72% women, 75% Hispanic, 88% pre-
scribed ≥1 BP medication. In unadjusted analyses, adherence was 
lower for beta-blockers (70.9%) compared to angiotensin receptor 
blocking agents (75.0%, P = 0.11), diuretics (75.9%, P < 0.001), calcium 
channel blockers (77.6%, P < 0.001) and angiotensin-converting enzyme 
inhibitors (78.0%, P < 0.0001). In the adjusted analysis, only dosing fre-
quency (P  =  0.0001) but not drug class (P = 0.71) was associated with 
medication adherence.
CONCLUSIONS
Antihypertensive drug class was not associated with electronically 
measured adherence after accounting for dosing frequency amongst 
patients with uncontrolled hypertension. Low adherence to beta-
blockers may have been due to the common practice of prescribing 
multiple daily dosing. Providers may consider using once daily formula-
tions to optimize adherence and should assess adherence among all 
treated patients with uncontrolled hypertension.
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would be lowest in patients prescribed beta-blockers and 
diuretics.
METHODS
Between February 2011 and June 2014, we enrolled a con-
venience sample of patients with treated but uncontrolled 
hypertension attending two urban, academic hospital-based 
primary care clinics (Columbia University Medical Center 
and Mount Sinai Medical Center). The study was approved 
by the Institutional Review Boards at both institutions. 
Patients were eligible if they were at least 18  years of age, 
prescribed one or more BP medications and had uncon-
trolled hypertension (defined as a BP ≥ 140/90 mm Hg or 
≥130/80 mm Hg if diabetic or with chronic kidney disease 
(CKD) based on the Seventh Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) guidelines in place at the time of the 
study)12 on at least two consecutively scheduled visits with 
their primary care provider (PCP). Key exclusion criteria 
were BP at goal during the recruitment visit, inability to self-
manage medications (e.g., due to dementia or severe psychi-
atric illness), and unavailability for follow-up.
Each participant was then given a 4-compartment elec-
tronic pillbox (MedSignals; MedSignals Corporation) that 
records the date and time each compartment is opened. 
Each BP medication was stored in a separate compart-
ment and participants were monitored during the interval 
between recruitment and the subsequent clinic visit with the 
PCP. BP was measured by a research assistant according to a 
standard protocol using an automatic BP machine (BpTRU, 
VSM MedTech, Vancouver, Canada)13 and was defined as 
the average of the second and third BP measured.
Measures
The main outcome variable was class  level medication 
adherence, a continuous variable defined as the percent of 
monitored days that the patient took the correct number 
of doses of a particular medication. If a participant took 1 
out of 2 doses on a given day, this counted as 50% adher-
ence that day. Participants were not penalized for taking 
extra doses. Days on which patients were hospitalized or 
had a clear history of traveling without their electronic pill-
box were censored. In descriptive analyses, adherence was 
defined as a dichotomous variable, and patients who took 
medications as prescribed less than 80% of days monitored 
were categorized as nonadherent.14 The main predictor was 
antihypertensive drug class as assessed by review of the elec-
tronic medical record. Antihypertensive medications were 
assigned to one of the following classes: thiazide diuretics, 
beta-blockers, ARBs, ACEIs, CCBs, or other. Medications 
that combined medications in one pill were included in the 
“other” category.
Age, gender, race, ethnicity, years of schooling, and health 
insurance status were assessed by self-report. Comorbidities, 
including diabetes mellitus, coronary artery disease (CAD), 
and heart failure, as well as total number of BP medications 
were based on chart review, and in the case of CKD, the most 
recent labs.
Cohort assembly
A total of 522 patients were screened. Of the patients 
who were screened, only 8.8% declined to participate and 
198 participants consented and completed a baseline inter-
view following their PCP visit. Compared to those who con-
sented, those who declined to participate were less likely to 
be Hispanic (56.1% vs. 76.9%, P < 0.001) and more likely to 
be black (70.7% vs. 48.2%; P < 0.001), but did not differ by 
gender. Of these 198 participants, we included 149 patients 
in the final analyses due to incomplete electronic adherence 
data (24.7%).
Statistical analysis
Descriptive statistics were used to describe the overall 
study population. To account for multiple BP medications 
within patients, mixed effects regression analyses were used 
to assess the association between drug class and mean per-
cent of days adherent. Based on prior systematic reviews of 
predictors of adherence to cardiovascular medications,6,15 
we adjusted for age, gender, ethnicity, race, health insurance 
status, years of schooling, number of BP medications, and 
frequency of dosing. We additionally adjusted for comor-
bidities with indications for specific drug classes in recent 
hypertension guidelines (i.e., CAD, heart failure, CKD, dia-
betes). We performed a sensitivity analysis in which we lim-
ited our analysis to participants with at least two weeks of 
adherence monitoring. As this did not significantly change 
any of our results, we only display the results on the com-
plete set of participants with any adherence monitoring. 
Additionally, as the distribution of mean percent of days 
adherent was negatively skewed, we performed a sensitivity 
analysis in which we transformed our measure of adherence 
to a measure of nonadherence (i.e., one adherence) and then 
applied a square-root transformation so that our depend-
ent variable approached a normal distribution. There were 
no differences in the pattern of the relationship between 
drug class and adherence. As such, we present data for the 
untransformed measure of adherence in order to simplify 
the interpretation of our findings.
RESULTS
Data pertaining to a total of 353 BP medications pre-
scribed by 33 PCPs among 149 participants were analyzed. 
The mean age was 64.2 years; 72% female, 41% Black, and 
75% Hispanic (See Supplementary Table S1 online). The 
mean systolic BP at baseline was 158 (20) mm Hg; 15% 
had CAD, 9% heart failure, and 58% diabetes. On average, 
participants were monitored for 55 days, range 6–365 days, 
and 93.3% had at least two weeks of adherence monitoring. 
Beta-blockers were the most commonly prescribed drug 
class (55%). The mean (SD) number of BP medications 
was 2.5 (0.93), and 88% were prescribed more than one BP 
medication.
The mean percent of days adherent for each drug class 
was lowest for beta-blockers (70.9%) compared to ARBs 
(75.0%, P  =  0.11), diuretics (75.9%, P  <  0.001), CCBs 
(77.6%, P  <  0.001), and ACEIs (78.0%, P  <  0.0001) (See 
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Supplementary Figure S1 online). The proportion of indi-
viduals who were adherent, defined as taking their medi-
cations more than 80% of days monitored, was lowest for 
beta-blockers (48%), followed by ARBs (50%), diuretics 
(56%), CCBs (60%), and ACEIs (70%). In the mixed effects 
analyses, a significant association between drug class and 
mean percent of days adherent was observed. In the unad-
justed model, adherence to beta-blockers was lower than all 
other drug classes (4.2% lower than ARBs (P = 0.11), 5.0% 
lower than diuretics (P  <  0.001), 6.7% lower than CCBs 
(P  <  0.001), and 7.1% lower than ACEIs (P  <  0.0001). In 
the adjusted model, dosing frequency was strongly asso-
ciated with medication adherence (B (SE)  =  −10.5 (2.1), 
P = 0.0001) (Table 1).
In post hoc analyses, we observed that once a day for-
mulations comprised 100% of diuretics, 98.3% of ACEIs, 
98.7% of CCBs, 97.5% of ARBs, 72.7% of “other” drugs, and 
39.0% of beta-blockers. We additionally compared the fully 
adjusted model excluding dosing frequency with a model 
that included dosing frequency. The association between 
beta-blockers and adherence was diminished only after add-
ing dosing frequency to the model (Table 1). Additionally, 
we stratified by frequency. Drug class was not related to 
adherence amongst those taking medications with once 
daily dosings (P = 0.41) or multiple daily dosings (P = 0.58). 
Finally, we stratified by number of BP medications. Amongst 
those on more than one BP agent, there was a significant 
relationship between drug class and adherence (P  =  0.01), 
which diminished by a similar magnitude after adjusting for 
frequency (P  =  0.64). Only 18 individuals were on mono-
therapy and we did not have sufficient power to assess class 
differences in this subgroup (P = 0.54).
DISCUSSION
Among patients with persistently uncontrolled hyperten-
sion on predominantly multi-BP drug regimens, we found 
suboptimal adherence across all classes of BP medications, 
but particularly for beta-blockers. The association between 
beta-blockers and nonadherence was likely explained by 
the increased propensity for beta-blockers to be prescribed 
as multiple doses per day. To our knowledge, this is the 
first study to compare and comprehensively electronically 
measure adherence to the near complete BP regimen simul-
taneously. Physicians often rely on beta-blockers to treat 
hypertension in patients with established cardiovascular dis-
ease or those already on several agents,16 such as our cohort 
where beta-blockers were the most frequently prescribed 
antihypertensive medication. In the United States, twice a 
day formulations of beta-blockers continue to be more com-
monly prescribed than once a day formulations,17 also dem-
onstrated in our cohort. Given recent studies supporting 
reduced adherence to beta-blockers and the now widespread 
availability of generic extended-release formulations,18 phy-
sicians should consider beta-blockers with proven efficacy 
and once daily dosing.16
Table 1. Mixed regression analysis of the association between antihypertensive drug class and mean % of days adherent to 
antihypertensive medications (estimate (SD), P value)
Drug class Model 1 Model 2 Model 3
Beta-blockers Ref Ref Ref
ARB 4.2 (2.6), P = 0.12 4.7 (2.7), P = 0.09 −2.5 (2.9), P = 0.41
ACEI 7.1 (1.4), P < 0.0001 6.3 (1.4), P < 0.0001 0.5 (1.7), P = 0.76
Diuretics 5.0 (1.6), P < 0.001 7.4 (1.6), P < 0.0001 0.5 (1.9), P = 0.80 
CCB 6.7 (1.7), P < 0.001 7.9 (1.6), P < 0.0001 −0.4 (2.2), P = 0.87 
Age 0.3 (0.3), P = 0.21 0.3 (0.3), P = 0.19
Gender −5.3 (5.2), P = 0.31 −4.1 (5.1), P = 0.43 
Race 0.2 (5.3), P = 0.98 0.5 (5.2), P = 0.91 
Ethnicity −4.1 (6.6), P = 0.54 −6.3 (6.6), P = 0.33 
# BP meds −2.3 (2.4), P = 0.38 −2.4 (2.4), P = 0.32 
CAD −6.8 (6.6), P = 0.31 −4.4 (6.5), P = 0.50
Heart failure −6.0 (7.3), P = 0.42 −5.3 (7.3), P = 0.46
DM 0.97 (4.7), P = 0.84 0.6 (4.7), P = 0.90
CKD 1.3 (4.7), P = 0.79 2.2 (4.7), P = 0.64 
Daysa −0.001 (0.1), P = 0.99 0.02 (0.1), P = 0.78
Medicaid 5.5 (6.6), P = 0.41 5.8 (6.6), P = −0.33
Education −0.5 (0.6), P = 0.43 −0.5 (0.6), P = 0.38
Dosing frequency −10.5 (2.1), P = 0.0001
Abbreviations: ARB, angiotensin II type 1 receptor blocking agents; ACEI, angiotensin II converting enzyme inhibitors; CCB, calcium channel 
blockers; CAD, coronary artery disease; CKD, chronic kidney disease. Significant terms are in bold.
aNumber of days monitored. 
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In contrast with our hypothesis, adherence to thiazide 
diuretics was not lower than adherence to other drug classes. 
We postulated that diuretics would be skipped or discon-
tinued more frequently due to side effects and electrolyte 
abnormalities. It is possible that side-effects are less discern-
able in multidrug regimens or that there was too short a 
period to observe discontinuation for electrolyte abnormali-
ties; it may also have been that participants with this cause 
of early discontinuation had already switched to different 
classes of drugs5 given that the majority of our patients were 
on long-term regimens. In contrast with prior studies using 
refill data, ARBs did not account for the highest adherence 
rates in our sample, possibly due to the small sample of 
patients prescribed ARBs in our cohort. It may be that the 
newness of product, financial incentives, market availability, 
and selection bias previously attributed to the superiority of 
ARB adherence compared to other classes6,19,20 in older stud-
ies have diminished over time.
There were several strengths to our study. We used elec-
tronic monitors to objectively measure medication adher-
ence, widely considered to be an optimal approach to 
measuring adherence. We also enrolled a racially and eth-
nically diverse sample from two primary care clinics. There 
were some limitations, however. Firstly, our findings in this 
primarily Medicaid, Hispanic population attending aca-
demic hospital-based clinics may not be generalizable to 
other populations. However, this is an understudied popu-
lation in whom little is known about adherence patterns. 
Though the majority of participants had Medicaid, we were 
unable to assess whether differences in co-pays or drug costs 
affected adherence. Also, unlike studies of pharmacy refill 
data, we had relatively short monitoring periods. While per-
sistence rates have been shown to diminish over time,5 we 
were unable to assess whether drug classes differed in terms 
of persistence, discontinuation, and class  change. Further, 
our method of measuring adherence via an electronic pillbox 
may have altered participants’ usual adherence behavior, as 
patients were aware they were being monitored and that this 
information might be relayed to their PCPs. Nevertheless, 
we still observed substantial non-adherence in our partici-
pants. Unlike large pharmacy refill data sets, our sample size 
was limited. Nonetheless, this is the first study to electroni-
cally measure adherence to multiple BP medications concur-
rently in such a large group of patients.
Despite these limitations, using electronic monitoring, 
we found suboptimal adherence across all drug classes 
and further research should be directed at interventions 
that improve these rates. Clinicians should carefully assess 
for nonadherence in patients with uncontrolled hyperten-
sion regardless of the class of antihypertensive medica-
tion prescribed. Strategies such as education, addressing 
barriers, and motivational interviewing have been used to 
address medication nonadherence with variable success.9 
Our results also remind clinicians to consider once-daily 
beta-blockers whenever possible, carefully ensuring that the 
once-per-day formulation is affordable to the patient. Future 
studies should seek to better understand why beta-blockers 
are more likely to be prescribed as a multiple daily dose drug 
and could explore interventions that remind physicians of 
the availability of extended release formulations.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American 
Journal of Hypertension (http://ajh.oxfordjournals.org).
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